Tiverton Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Tiverton Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$20K	Buy	+2,006	New	+$24.6K	﹤0.01%	706

Other funds holding MIRM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Tiverton Asset Management's MIRM Position: Q3 2019 in Review

Tiverton Asset Management opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2019: 2,006 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #706 among its holdings.

39 funds tracked by Wall St. Rank hold MIRM as of Q3 2019.

Tiverton Asset Management held 2,006 shares of Mirum Pharmaceuticals worth $20K as of Q3 2019.
Mirum Pharmaceuticals was a new Tiverton Asset Management position in Q3 2019.
Mirum Pharmaceuticals made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #706 holding.
39 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.